Mizuho analyst Uy Ear lowered the firm’s price target on Selecta Biosciences to $3 from $4 and keeps a Buy rating on the shares. With the termination of effectively all pipeline development, Selecta “has the potential to become an attractive entity to play,” the analyst tells investors in a research note. The firm now sees a “significantly leaner” pure royalty-generating play.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SELB:
- Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
- Selecta Biosciences expects cash to fund operations into 2027
- Selecta Biosciences reports Q2 EPS (7c), consensus (8c)
- SELB Earnings this Week: How Will it Perform?
